Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
11 studies found for:    "Plasma cell leukemia"
Show Display Options
Download search resultsDownload the search results for:
"Plasma cell leukemia" (11 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia
Condition: Primary Plasma Cell Leukemia
Intervention: Drug: Lenalidomide, dexamethasone
2 Recruiting Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Conditions: Plasma Cell Leukemia;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Liposome doxorubicin;   Drug: Dexamethasone
3 Active, not recruiting Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Conditions: Multiple Myeloma;   Multiple Myeloma in Relapse;   Mantle Cell Lymphoma in Relapse;   Diffuse Large B Cell Lymphoma in Relapse;   Other B Cell Lymphoma in Relapse;   Plasma Cell Leukemia
Intervention: Biological: SNS01-T
4 Completed
Has Results
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: PBSCT
5 Not yet recruiting Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
6 Active, not recruiting Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: Fludarabine/Busulfan x 4 days;   Procedure: stem cell transplant
7 Active, not recruiting A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;   Drug: Dexamethasone, steroid; oral
8 Active, not recruiting A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous;   Drug: Dexamethasone, steroid; oral;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
9 Terminated Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
Conditions: Multiple Myeloma;   Leukemia, Plasma Cell
Interventions: Drug: Carfilzomib;   Drug: Melphalan;   Drug: Filgrastim
10 Completed Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: bortezomib;   Drug: dexamethasone;   Drug: thalidomide;   Drug: Aspirin
11 Recruiting Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim

Indicates status has not been verified in more than two years